A new study by researchers at CHOP and Penn has identified an important role for a non-classical MHC molecule that engages with a cryptic viral peptide derived from influenza A virus.

A Penn Medicine and CHOP team will seek to develop treatments for three rare, incurable genetic diseases with the help of a $26 million grant from the National Institutes of Health.

In the largest study of its kind, CHOP researchers have validated a population-level pattern of pediatric allergy development known as the “allergic march.”

Tool may be more accurate than existing methods and was made possible through a cohort of tens of thousands of patients from different backgrounds around the world.

Children’s Hospital of Philadelphia (CHOP) researcher Riccardo Gottardi, PhD has been named a “Young Innovator of Cellular and Molecular Bioengineering” by Cellular and Molecular Bioengineering, the official journal of the Biomedical Engineering Society.

“Nudges” from electronic health records could improve the implementation of tobacco use treatment almost three-fold over standard care.

CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.

CHOP researchers have shown that NSAIDs disrupt epithelial cells in the colon and sensitize them to C. difficile toxins by perturbing cell mitochondria.

CHOP researchers suggest more targeted intervention against discrimination, particularly in states with higher rates of structural stigma.

CHOP and Penn researchers have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders directly within the body.